LOG IN
SIGN UP
MARKET
MEIP
MEIP
Mei Pharma Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.4261
+0.0090
+2.16%
Pre Market: 0.4450 +0.0189 +4.44% 08:21 05/27 EDT
OPEN
0.4245
PREV CLOSE
0.4171
HIGH
0.4466
LOW
0.4130
VOLUME
945
TURNOVER
--
52 WEEK HIGH
3.550
52 WEEK LOW
0.4050
MARKET CAP
56.74M
P/E (TTM)
-0.8879
1D
5D
1M
3M
1Y
5Y
MEI Pharma And Kyowa Kirin Announce Acceptance Of Abstract For Presentation At The American Society Of Clinical Oncology Annual Meeting 2022
MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating
Benzinga · 18h ago
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
SAN DIEGO & TOKYO, May 26, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating inno...
Business Wire · 18h ago
BRIEF-MEI Pharma Posts Q3 Loss Per Share Of 7 Cents
reuters.com · 3d ago
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
MEI Pharma GAAP EPS of -$0.07 beats by $0.11, revenue of $9.7M beats by $6.26M
MEI Pharma press release (NASDAQ:MEIP): Q3 GAAP EPS of -$0.07 beats by $0.11. Revenue of $9.7M (+19.8% Y/Y) beats by $6.26M.
Seekingalpha · 3d ago
MEI Pharma Q3 Net Loss Narrows; Revenue Increases Almost 20%
MT Newswires · 3d ago
-- Earnings Flash (MEIP) MEI PHARMA Posts Q3 Revenue $9.7M
MT Newswires · 3d ago
MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
SAN DIEGO, May 17, 2022--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright Global Investment Conference 2022. The company will presen...
Business Wire · 05/17 12:00
No Data
Learn about the latest financial forecast of MEIP. Analyze the recent business situations of Mei Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 10 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
10.00%Strong Buy
50.00%Buy
40.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MEIP stock price target is 5.30 with a high estimate of 15.00 and a low estimate of 1.000.
Current 0.4436
EPS
Actual
Estimate
-0.22-0.17-0.11-0.06
Institutional Holdings
Institutions: 129
Institutional Holdings: 70.87M
% Owned: 53.29%
Shares Outstanding: 133.15M
TypeInstitutionsShares
Increased
35
3.95M
New
18
2.50M
Decreased
20
7.47M
Sold Out
34
31.73M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.28%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Non-Executive Chairman/Independent Director
Christine White
Chief Executive Officer/President/Director
Daniel Gold
Chief Operating Officer/General Counsel
David Urso
Senior Vice President
Yomara Gomez-Naiden
Senior Vice President
Alejandro Ricart
Other
Richard Ghalie
Director
Sujay Kango
Independent Director
Charles Baltic
Independent Director
Cheryl Cohen
Independent Director
Frederick Driscoll
Independent Director
Nicholas Glover
Independent Director
Tamar Howson
Independent Director
Thomas Reynolds
No Data
No Data
About MEIP
MEI Pharma, Inc. is a late-stage pharmaceutical company. The Company is focused on development and commercialization of novel cancer therapies. The Company's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The Company is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS).
Webull offers kinds of MEI Pharma Inc stock information, including NASDAQ:MEIP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEIP stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading MEIP stock methods without spending real money on the virtual paper trading platform.